Horizon Therapeutics market cap is $15.6 b, and annual revenue was $1.30 b in FY 2019

Horizon Therapeutics Gross profit (Q3, 2020)485 M

Horizon Therapeutics Gross profit margin (Q3, 2020), %76.2%

Horizon Therapeutics Net income (Q3, 2020)292.8 M

Horizon Therapeutics EBIT (Q3, 2020)228.6 M

Horizon Therapeutics Cash, 30-Sept-20201.7 B

Horizon Therapeutics EV14.8 B

Horizon Therapeutics revenue was $1.30 b in FY, 2019 which is a 7.7% year over year increase from the previous period.

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Revenue | 1.1b | 1.2b | 1.3b |

| 14% | 8% | |

## Cost of goods sold | 546.3m | 422.3m | 362.2m |

## Gross profit | 510.0m | 785.3m | 937.9m |

| 48% | 65% | 72% |

## R&D expense | 225.0m | 82.8m | 103.2m |

## General and administrative expense | 677.4m | 692.5m | 697.1m |

## Operating expense total | 902.3m | 782.9m | 811.2m |

## EBIT | (392.4m) | 2.4m | 126.6m |

| (37%) | 0% | 10% |

## Interest expense | 126.5m | 121.7m | 87.1m |

## Pre tax profit | (513.3m) | (119.1m) | (20.2m) |

## Income tax expense | (102.7m) | (45.0m) | (593.2m) |

## Net Income | (410.5m) | (74.2m) | 573.0m |

## EPS | (2.5) | (0.4) | 3.1 |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 223.9m | 302.8m | 325.3m | 280.4m | 320.6m | 335.5m | 355.9m | 462.8m | 636.4m |

## Cost of goods sold | 116.1m | 100.1m | 99.0m | 88.1m | 89.2m | 89.9m | 97.4m | 121.5m | 151.5m |

## Gross profit | 107.8m | 202.8m | 226.3m | 192.2m | 231.5m | 245.5m | 258.5m | 341.3m | 485.0m |

| 48% | 67% | 70% | 69% | 72% | 73% | 73% | 74% | 76% |

## R&D expense | 17.6m | 24.3m | 21.2m | 21.7m | 28.3m | 24.6m | 27.2m | 81.1m | 30.2m |

## General and administrative expense | 179.6m | 176.7m | 161.6m | 172.3m | 167.1m | 172.3m | 247.8m | 222.2m | 226.2m |

## Operating expense total | 235.1m | 200.9m | 172.1m | 194.0m | 206.4m | 196.9m | 275.0m | 303.4m | 256.4m |

## EBIT | (127.3m) | 1.8m | 54.2m | (1.8m) | 25.1m | 48.6m | (16.5m) | 37.9m | 228.6m |

| (57%) | 1% | 17% | (1%) | 8% | 14% | (5%) | 8% | 36% |

## Interest expense | 30.5m | 31.0m | 30.4m | 27.5m | 22.0m | 20.4m | 17.3m | 18.6m | 12.2m |

## Pre tax profit | (157.7m) | (28.9m) | 24.3m | (34.8m) | (10.0m) | (12.3m) | (32.6m) | 3.0m | 201.8m |

## Income tax expense | (367.0k) | 4.0m | (1.7m) | (1.9m) | (4.9m) | (30.6m) | (19.0m) | 83.0m | (91.1m) |

## Net Income | (157.3m) | (32.8m) | 26.0m | (32.9m) | (5.1m) | 18.2m | (13.6m) | (80.0m) | 292.8m |

## EPS | (1.0) | (0.2) | 0.2 | (0.2) | 0.0 | 0.1 | (0.1) | (0.4) |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Cash | 751.4m | 958.7m | 1.1b |

## Accounts Receivable | 367.4m | 464.7m | 408.7m |

## Inventories | 61.7m | 50.8m | 53.8m |

## Current Assets | 1.2b | 1.5b | 1.7b |

## PP&E | 20.4m | 20.1m | 30.2m |

## Goodwill | 426.4m | 426.4m | 413.7m |

## Total Assets | 4.2b | 4.1b | 4.4b |

## Accounts Payable | 34.7m | 30.3m | 21.5m |

## Short-term debt | 10.6m | ||

## Current Liabilities | 757.1m | 761.9m | 723.2m |

## Long-term debt | 1.6b | 1.6b | 1.4b |

## Non-Current Liabilities | 2.4b | 2.3b | 1.5b |

## Total Debt | 1.6b | 1.6b | 1.4b |

## Common Stock | 16.0k | 17.0k | 19.0k |

## Additional Paid-in Capital | 2.2b | 2.4b | 2.8b |

## Retained Earnings | (1.3b) | (1.3b) | (605.7m) |

## Total Equity | 991.1m | 1.1b | 2.2b |

## Debt to Equity Ratio | 1.6 x | 1.5 x | 0.6 x |

## Debt to Assets Ratio | 0.4 x | 0.4 x | 0.3 x |

## Financial Leverage | 4.2 x | 3.9 x | 2 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Net Income | (410.5m) | (74.2m) | 573.0m |

## Depreciation and Amortization | 283.4m | 275.7m | 237.2m |

## Accounts Receivable | (61.8m) | (59.7m) | 56.2m |

## Inventories | 108.4m | 10.3m | (3.3m) |

## Accounts Payable | (16.5m) | (4.6m) | (8.7m) |

## Cash From Operating Activities | 280.2m | 194.5m | 426.3m |

## Purchases of PP&E | (4.3m) | (4.8m) | (17.9m) |

## Cash From Investing Activities | (101.6m) | 27.7m | (17.9m) |

## Long-term Borrowings | (1.6b) | (845.7m) | (2.2b) |

## Cash From Financing Activities | 58.4m | (16.6m) | (290.4m) |

## Net Change in Cash | 242.3m | 204.2m | 117.9m |

## Interest Paid | 113.8m | 112.5m | 78.0m |

## Income Taxes Paid | 2.5m | 53.1m | 9.9m |

USD | FY, 2017 |
---|---|

## EV/EBIT | -8.2 x |

## EV/CFO | 11.5 x |

## Revenue/Employee | 1.0m |

## Debt/Equity | 1.6 x |

## Debt/Assets | 0.4 x |

## Financial Leverage | 4.2 x |

## P/E Ratio | (5.8) |